SEL Injectables Service - Inclisiran

This webinar will introduce the new SEL Injectables service, with a focus on the inclisiran element of the service. It will cover eligibility under NICE TA733 for patients with established atherosclerotic cardiovascular disease and persistently raised LDL-C despite maximum tolerated lipid-lowering therapy. The session will explore the clinical rationale for inclisiran and its place within the lipid pathway, alongside practical guidance on the operational model, identifying eligible patients, initiation and maintenance dosing, coding, storage and administration. We will also cover how practices can sign up to the scheme, current treatment targets, and where to access relevant guidance and resources. By the end of the webinar, you will have a clearer understanding of the inclisiran service and increased confidence in identifying and managing eligible patients within the primary care setting.